NCT00330343View on ClinicalTrials.gov

Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
PainNauseaPruritus
Interventions
DRUG

naloxone

continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour

Trial Locations (1)

21287

John Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT00330343 - Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents | Biotech Hunter | Biotech Hunter